Regulatory authorities in Spain and Poland have approved the inclusion of Multiple System Atrophy (MSA) patients in BioArctic's ongoing EXIST Phase 2a trial of exidavnemab, an alpha-synuclein antibody.
The US FDA has granted orphan drug designation to exidavnemab, BioArctic's monoclonal antibody targeting alpha-synuclein aggregates, for the treatment of Multiple System Atrophy.
BioArctic secures landmark licensing agreement with Bristol Myers Squibb worth up to $1.35 billion plus royalties for antibodies BAN1503 and BAN2803 targeting Alzheimer's disease.
BioArctic has dosed the first subject in its Phase IIa EXIST trial evaluating exidavnemab, a monoclonal antibody, for the treatment of Parkinson's disease.